“o. itemList. length” “this. config. text. ariaShown”
“This. config. text. ariaFermé”
BUENOS AIRES, 2 Nov (Reuters) – Argentina expects 10 million doses of Russia’s main experimental vaccine opposed to COVID-19 between December and January, the government said Monday, as infections continue in the South American country.
The vaccine, known as Sputnik V, is given in two doses and could begin arriving next month, the government said in a press release. The value of the Russian vaccine would be “more or less average” for others. President Alberto Fernandez said in the statement.
“We had a proposal from the Russian Ministry of Foreign Affairs and the Russian Direct Investment Fund to see if Argentina was interested in receiving doses of the vaccine in December and of course we said yes,” Fernandez said.
The Russian Direct Investment Fund (DRIF) supports the progression and deployment of the Sputnik V vaccine. Fernandez said discussions with RDIF had been ongoing “for some time. “Officials, Argentina’s deputy fitness minister, have visited Russia to review the progression of the vaccine, the government said.
“The Sputnik V vaccine for Argentina will be produced through RDIF partners in India, Korea, China and several countries that are implementing vaccine production in Russia,” RDIF CEO Kirill Dmitriev said in shared comments through a company. Spokesman.
DrIF said friday that it had introduced the initial document submission procedure to neighboring Brazil, a step to sign the vaccine for use there.
Despite the Argentine government’s strict blockade to stop the spread of the virus from mid-March, coronavirus cases continue to increase: the South American country surpassed one million contagions last month and more than 30,000 deaths.
It has at least 19 legal clinical trials for COVID-19 vaccines, according to data from the Ministry of Health, Pfizer Inc. and Johnson’s Janssen unit.
Argentina also agreed in August to co-produce with Mexico and the uk’s largest drug manufacturer in the UK, AstraZeneca Plc, a possible vaccine opposed to the progression of the virus at the University of Oxford.
(Report through Anthony Boadle, Eliana Raszewski and Cassandra Garrison in Buenos Aires edited through Matthew Lewis)